Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-06-06
1995-11-07
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
424 852, 436 86, 436 87, 514 21, 530412, A61K 3817, A61K 3818, C07K 114, G01N 3368
Patent
active
054648157
ABSTRACT:
The invention provides a method for extending the plasma half-life of heparin-binding proteins by coadministering such proteins with a therapeutically acceptable compound capable of inhibiting their binding to a low affinity heparin-like binding site on the surface of cells. In one embodiment of the invention, the-heparin-binding protein is a selectin. The binding inhibitory compound can, for example, be a purified native heparin preparation, a heparin fragment, or another polyanionic compound, such as dextran sulfate, heparan sulfate, pentosan sulfate, or hyaluronate.
REFERENCES:
patent: 4844895 (1989-07-01), Thorbecke et al.
patent: 4889808 (1989-12-01), Rappaport
patent: 5057494 (1991-10-01), Sheffield
patent: 5110604 (1992-05-01), Chu et al.
patent: 5130143 (1992-07-01), Strickland et al.
patent: 5175147 (1992-12-01), Folkman et al.
patent: 5227158 (1993-07-01), Jardieu
patent: 5234908 (1993-08-01), Szabo et al.
patent: 5262298 (1993-11-01), Shipley et al.
patent: 5288704 (1994-02-01), Ungheri et al.
patent: 5314872 (1994-05-01), Kato et al.
patent: 5318890 (1994-06-01), Rosen et al.
patent: 5389520 (1995-02-01), Tedder et al.
The Lancet, Issued 14 Apr. 1979, Poschmann et al, "Exchange Transfusion with Heparinised Fresh Blood . . . ", pp. 824-825.
J. Cell. Physiology, vol. 140 Issued 1989, Barzu et al, "Heparin-Derived Oligosaccharides . . . ", pp. 538-548.
J. Cell Biology, vol. 107 Issued Aug. 1988, Moscatelli, "Metabolism of Receptor-Bound and Matrix-Bound . . . ", pp. 753-759.
J. Cell. Physiology, vol. 140, Issued 1989, Mueller et al, "Stabilization by Heparin of Acidic Fibroblast . . . ", pp. 439-448.
J. Cell Biology, vol. 107, Issued Aug. 1988, Saksela et al, "Endothelial Cell-Derived Heparan. Sulfate . . . ", pp. 743-751.
PNAS USA, vol. 82 Issued Oct. 1985, Thomas et al, "Pure Brain-Derived Acidic Fibroblast Growth Factor . . . ", pp. 6409-6413.
Cell, vol. 64 Issued 22 Feb. 1991, Yayon et al, "Cell Surface, Heparin-Like Molecules Are Required . . . ", pp. 841-848.
Liu et al., "Importance of the Liver in Plasma Clearance of Hepatocyte Growth Factor in Rats," Am. J. Physiol. 263 (Gastrointest. Liver Physiol. 26): G642-G649 (1992).
Loscalzo et al., "The Interaction of Platelet Factor Four and Glycosaminoglycans," Arch. Biochem. Biophys. 240, 446-455 (1985).
Norgard-Sumnicht et al., "Calcium-Dependent Heparin-Like Ligands for L-Selectin in Nonlymphoid Endothelial Cells," Science, 261, 480-483 (1993).
Soker et al., "Vascular Endothelial Growth Factor is Inactivated by Binding to .alpha..sub.2 -Macroglobulin and the Binding Is Inhibited by Heparin," J. Biol. Chem. 268(11): 7685-7691 (1993).
Sugiyama et al., "Receptor-Mediated Transport of Peptide Hormones and Its Importance in the Overall Hormone Disposition in the Body," Pharm. Res. 6, 192-202 (1989).
Sugiyama et al., "Receptor-Mediated Disposition of Polypeptides: Kinetic Analysis of the Transport of Epidermal Growth Factor as a Model Peptide Using In Vitro Isolated Perfused Organs and In Vivo System," J. Controlled Release 13, 157-174 (1990).
Sugiyama et al., Receptor Mediated Hepatic Clearance of Peptide Hormones, In: Topics in Pharmaceutical Sciences 1989, Breimer et al., eds., Elsevier, New York, 1989, pp. 429-443 (Will be submitted upon receipt.).
Talpas et al., "H-NMR Studies of Bovine Platelet Factor 4: Histidine Assignments and Interactions with Heparin," Biochim. Biophys. Acta 1078, 208-218 (1991).
Tyrrell et al., "Structure and Biological Activities of a Heparin-Derived Hexasaccharide with High Affinity for Basic Fibroblast Growth Factor," J. Biol. Chem. 268, 4684-4689 (1993).
Webb et al., "Binding to Heparan Sulfate or Heparin Enhances Neutrophil Responses to Interleukin 8," Proc. Natl. Acad. Sci. USA 90, 7158-7162 (1993).
Zucker et al., "Immunoregulatory Activity of Peptides Related to Platelet Factor 4," Proc. Natl. Acad. Sci. USA 86, 7571-7574 (1989).
Kobayashi, T. et al., "Hepatocyte Growth Factor Specifically Binds to Sulfoglycolipids," J. Biol. Chem. 269(13): 9817-9821 (1994).
Kobayashi, T. et al., "Hepatocyte Growth Factor Elevates the Activity Levels of Glycolipid Sulfotransferases in Renal Cell Carcinoma Cells," Eur. J. Biochem. 219: 407-413 (1994).
Matsumoto, K. et al., "Heparin as an Inducer of Hepatocyte Growth Factor," J. Biochem. 114: 820-826 (1993).
Mizuno, K. et al., "Hairpin Loop and Second Kringle Domain Are Essential Sites for Heparin Binding and Biological Activity of Hepatocyte Growth Factor," J. Biol. Chem. 269(2): 1131-1136 (1994).
Naka, D. et al., "Heparin Modulates the Receptor-Binding and Mitogenic Activity of Hepatocyte Growth Factor on Hepatocytes," Exp. Cell Res. 209: 317-324 (1993).
Barber et al., "Characterization of a Chondroitin .sub.4 -Sulfate Proteoglycan Carrier for Heparin Neutralizing Activity (Platelet Factor .sub.4) Released from Human Blood Platelets," Biochim. Biophys. Acta 286, 312-329 (1972).
Burgess and Maciag, "The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins," Annu. Rev. Biochem. 58, 576-606 (1989).
Gitay-Goren et al., "The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-Associated Heparin-Like Molecules," J. Biol. Chem. 267, 6093-6098 (1992).
Handin et al., "Purification and Binding Properties of Human Platelet Factor Four," J. Biol. Chem. 251, 4273-4282 (1976).
Ishihara et al., "Preparation of Affinity-Fractionated, Heparin-Derived Oligosaccharides and Their Effects on Selected Biological Activities Mediated by Basic Fibroblast Growth Factor," J. Biol. Chem. 268, 4675-4683 (1993).
Kim et al., "Kinetic Analysis of In Vivo Receptor-Binding of Human Epidermal Growth Factor by Rat Tissues," J. Pharm. Sci. 77, 200-207 (1988).
Klagsbrun, Prog. Growth Factor Res. 1, 207-235 (1989).
Chamow Steven
Modi Nishit
Schwall Ralph
Zioncheck Thomas
Dreger Ginger R.
Genentech Inc.
Marschang Diane L.
Russel Jeffrey E.
LandOfFree
Inhibition of heparin-binding does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of heparin-binding, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of heparin-binding will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-197245